-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Managing Toxicities of Bruton Tyrosine Kinase Inhibitors

Program: Education Program
Session: Managing Toxicities of Targeted Therapies in CLL
Hematology Disease Topics & Pathways:
Leukemia, Diseases, CLL, Therapies, Adverse Events, Lymphoid Malignancies
Saturday, December 5, 2020, 1:55 PM-2:00 PM

Nicole Lamanna, MD

Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

Disclosures: Lamanna: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bei-Gene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Astra Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Oncternal, Verastem, TG Therapeutics: Other: Institutional research grants, Research Funding; MingSight: Other: Institutional research grants, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Juno: Other: Institutional research grants, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Octapharma: Research Funding; Columbia University Medical Center: Current Employment; Loxo: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure:

See more of: Managing Toxicities of Targeted Therapies in CLL
See more of: Education Program
<< Previous Presentation | Next Presentation >>